Universitat de Girona

Web-CDSS HTE 3.0 familiar hypercolesterolimia

Posted by Universitat de GironaResponsive · Innovative Products and Technologies · Spain

Summary of the technology

The present technology is a Web application integrable in a public or private health system, which facilitates the detection of dyslipidemia in general, and familiar hypercholesterolemia in particular. WEB-CDSS HTE 3.0 allows to customize the hypolipidemic treatment, considering its cardiovascular risk, concomitant diseases and drugs.It is based on the European Dyslipemia Guidelines of 2016

Description of the technology

Cardiovascular diseases are the main cause of death worldwide. Atherosclerotic cardiovascular disease (ACD) is the leading cause of death and hospitalization. This mortality can be reduced up to 21% if optimal cholesterol (LDL-C) is obtained. Less than 20% of patients with very high cardiovascular risk achieve the goals, maintaining high cholesterol levels (alteration known as dyslipidemia).

ACD may be precocious if there is a family history, especially in familiar hypercholesterolemia (HF), where the genetic predisposition may reach up to 50%. HF occurs in 1/200 people. Only 10% of HF patients are properly diagnosed, and often through inefficient treatments

WEB-CDSS HTE 3.0 is a web application integrable in a public or private health system, which facilitates the detection of dyslipidemia in general, and HF in particular. WEB-CDSS HTE 3.0 allows to customize the hypolipidemic treatment, considering its cardiovascular risk, concomitant diseases and drugs, and proposing statin, ezetemibe or PCSK-9 inhibitors based treatments, ordered according criteria of efficacy, safety and efficiency. It is based on the European Dyslipemia Guidelines of 2016

Desired business relationship

This technology is Medicine field oriented, and specifically to the diagnosis of dyslipidemia and familial hypercholesterolemia. Its target includes health professionals, healthcare providers and pharmaceutical companiesThe deal sought is a license agreement, development agreement.

Competitive advantages

  • Represents an improvement in the overall diagnosis of dyslipidemia.
  • Improves the detection and management of familial hypercholesterolemia.
  • Improves the quality of prescription of hypolipidemic treatment to be followed.
  • Cost savings.

Intellectual property status

Other forms of protection

Copyright

Technology Owner

Universitat de Girona

Technology Transfer Office

Related keywords

  • Biological Sciences
  • Genetic Engineering / Molecular Biology
  • Medical Health related
  • Cardiology
  • cardiovascular disease
  • hypercholesterolemia
  • dyslipidemia
  • atherosclerotic cardiovascular disease

About Universitat de Girona

Technology Transfer Office from Spain

The University of Girona (UdG) by means of its Research & Technology Transfer Office (TTO) provides services to 117 research groups, 42 of which have been recognized as Consolidated Research Group of Catalonia and 4 among them have been incorporated into the TECNIO network, the top Catalonia's Government excellence research network.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.